Cannabidiol Fragile X Trial Fails to Meet Primary Endpoint – Hemp Gazette
Recent cannabidiol fragile x syndrome trial results demonstrate the challenges of translating preclinical cannabis research into effective treatments for neurodevelopmental disorders. This clinical analysis examines what the trial failure means for…
Maternal Cannabis Exposure and Risk of ASD ADHD in Offspring: A Systematic Review of Endocannabinoid System Research
Maternal cannabis exposure risk ASD is linked to modest increases in autism and ADHD in offspring. Cannabis crosses the placental barrier affecting fetal brain development. This research highlights the importance of counseling against cannabis use during…
Can medicinal cannabis help kids’ autism, ADHD or Tourette’s? Here’s what we know so far
Pediatric cannabis use autism research is emerging but remains limited and observational. Safety concerns for ADHD and Tourette's in kids require careful clinical consideration. Families and clinicians must weigh benefits against risks with limited data.
Phase 2 Open-Label INSPIRE Trial on Transdermal CBD Gel in 22q11.2 Deletion Syndrome
The INSPIRE trial investigates transdermal cannabidiol gel children with 22q11.2 deletion syndrome to assess safety and tolerability. This phase 2 open-label study provides preliminary data on CBD gel use in pediatric neurodevelopmental disorders.…
Tylenol and Autism: 7 Insights You Need Now
Tylenol has long been the go-to pain reliever during pregnancy, but a new wave of research questions its safety. This post unpacks the science, the panic, and the human stories behind the headlines on Tylenol and autism. The truth? It’s…
Single Center Experience with Medical Cannabis in Gilles de la Tourette Syndrome
Medical cannabis Gilles de la Tourette syndrome treatment shows promising symptom relief in a single center study. Patients reported reduced tic severity, better sleep, and improved mood. This study highlights the potential benefits of medical cannabis…